Short answer
Baxter International (BAX) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3.0B (up 5.0% year over year) with net income of $294M.
Q3 2026 key financials · XBRL
- Revenue
- $3.0B
- +5.0% YoY · +0.5% QoQ
- Net income
- $294M
- +739.1% YoY · +133.3% QoQ
- Operating margin
- 7.6%
- Gross margin
- 33.4%
- EPS (diluted)
- $0.57
- +733.3% YoY · +137.5% QoQ
Source: XBRL data from the Baxter International (BAX) Q3 2026 10-Q on SEC EDGAR. USD.
Baxter International Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2.976B, up $141M from $2.835B YoY, with Medical Products & Therapies strongest at 6% growth
- Gross margin 33.4% vs 33.5% YoY, excluding special items down 1.1 percentage points
- Advanced Surgery best-performing line, sales up 12%; Other sales weakest, $68M vs $85M YoY
- Operating cash flow $1.07B vs $355M YoY; debt repayments $600M and capital expenditures $363M
- Outlook: tariffs, supply constraints, inflation and geopolitical uncertainty remain headwinds; no meaningful Novum LVP sales during shipment holds
Risk Factors
- No material changes to risk factors disclosed in Baxter’s 2025 Annual Report
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Baxter International quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.